Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AGEN logo AGEN
Upturn stock ratingUpturn stock rating
AGEN logo

Agenus Inc (AGEN)

Upturn stock ratingUpturn stock rating
$4.57
Last Close (24-hour delay)
Profit since last BUY62.06%
upturn advisory
Consider higher Upturn Star rating
BUY since 46 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: AGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Year Target Price $11.5

Year Target Price $11.5

Analyst’s Price TargetsFor last 52 week
$11.5Target price
Low$1.38
Current$4.57
high$18.74

Analysis of Past Performance

Type Stock
Historic Profit -63.8%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 130.50M USD
Price to earnings Ratio 0.16
1Y Target Price 11.5
Price to earnings Ratio 0.16
1Y Target Price 11.5
Volume (30-day avg) 5
Beta 1.43
52 Weeks Range 1.38 - 18.74
Updated Date 06/29/2025
52 Weeks Range 1.38 - 18.74
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 29.61

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -191.5%
Operating Margin (TTM) -55.31%

Management Effectiveness

Return on Assets (TTM) -28.7%
Return on Equity (TTM) -1278.83%

Valuation

Trailing PE 0.16
Forward PE 2.82
Enterprise Value 204059206
Price to Sales(TTM) 1.31
Enterprise Value 204059206
Price to Sales(TTM) 1.31
Enterprise Value to Revenue 2.05
Enterprise Value to EBITDA -2.42
Shares Outstanding 27416800
Shares Floating 27014645
Shares Outstanding 27416800
Shares Floating 27014645
Percent Insiders 1.44
Percent Institutions 34.04

Analyst Ratings

Rating 3
Target Price 11.5
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Agenus Inc

stock logo

Company Overview

overview logo History and Background

Agenus Inc., founded in 1994 (originally Antigenics), is a biopharmaceutical company focused on developing and commercializing immunotherapies to treat cancer. It initially focused on heat shock protein-based vaccines and has evolved to focus on checkpoint modulators, cell therapies, and other immunotherapeutic approaches.

business area logo Core Business Areas

  • Checkpoint Modulators: Agenus develops and commercializes antibodies that target immune checkpoints, such as CTLA-4 and PD-1, to enhance the body's anti-cancer immune response.
  • Cell Therapies: Agenus is engaged in the discovery and development of adoptive cell therapies, including T-cell therapies, to target and eliminate cancer cells.
  • Vaccines: Agenus is exploring vaccine strategies to prime the immune system to recognize and attack cancer cells. Includes programs using QS-21 Stimulon adjuvant.

leadership logo Leadership and Structure

The leadership team includes Garo H. Armen as Chairman and CEO. The company is structured around research & development, clinical development, and commercialization functions.

Top Products and Market Share

overview logo Key Offerings

  • BALSTICALI (zalifrelimab-zlfg): A PD-1 blocking antibody approved for relapsed or metastatic cervical cancer in combination with chemotherapy. Agenus has partnered with Betta Pharmaceuticals for the Chinese market. Competitors include Keytruda (Merck), Opdivo (Bristol Myers Squibb), and Libtayo (Regeneron/Sanofi). Market share data is still evolving; however, Keytruda and Opdivo hold the majority of the PD-1 inhibitor market.
  • AGEN1181: AGEN1181 is a next-generation anti-CTLA-4 antibody designed to enhance anti-tumor activity while minimizing toxicity. Currently in clinical trials for various cancers. Competitors include Yervoy (Bristol Myers Squibb). No specific market share data is available yet as it is still under development.
  • QS-21 Stimulon adjuvant: A saponin-based vaccine adjuvant. Agenus has partnered with various companies for vaccines against different diseases. Competitors are dependent on the vaccine programs using this adjuvant. No significant revenue is publicly available for Agenusu2019s QS-21.

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is experiencing substantial growth, driven by the increasing prevalence of cancer and the clinical success of immunotherapeutic agents like checkpoint inhibitors and cell therapies. The market is competitive, with both established pharmaceutical companies and emerging biotech firms.

Positioning

Agenus is positioned as an innovative immunotherapy company with a focus on developing novel checkpoint modulators, cell therapies, and vaccine adjuvants. Its competitive advantage lies in its discovery platforms and proprietary technologies, although its current market share is small compared to larger pharmaceutical companies.

Total Addressable Market (TAM)

The global immunotherapy market is projected to reach hundreds of billions of dollars annually. Agenus is positioned to capture a share of this market through its pipeline of clinical and preclinical assets.

Upturn SWOT Analysis

Strengths

  • Innovative immunotherapy pipeline
  • Proprietary discovery platforms
  • Experienced leadership team
  • Strategic partnerships

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on clinical trial success
  • Competition from established players
  • History of net losses

Opportunities

  • Expanding immunotherapy market
  • Potential for new drug approvals
  • Strategic collaborations and licensing agreements
  • Advancements in cell therapy and vaccine technologies

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other immunotherapy companies
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • REGN
  • AZN

Competitive Landscape

Agenus faces intense competition from larger pharmaceutical companies with established immunotherapy franchises. Agenus's advantages include its innovative pipeline and proprietary technologies. Its disadvantages include limited financial resources and a smaller commercial infrastructure.

Major Acquisitions

4-Antibody AG

  • Year: 2014
  • Acquisition Price (USD millions): 15
  • Strategic Rationale: Expanded antibody discovery capabilities and strengthened the company's pipeline of immuno-oncology candidates.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by strategic collaborations and advancements in the company's pipeline. The company's success has been limited by the fact that the company has been in a net loss position for years.

Future Projections: Future growth is contingent on the success of clinical trials, regulatory approvals, and commercialization of its immunotherapy products. Analyst estimates are based on assumptions about the potential of Agenus's pipeline.

Recent Initiatives: Recent initiatives include advancing clinical trials for its checkpoint modulators and cell therapies, expanding partnerships, and seeking regulatory approvals for its lead product candidates.

Summary

Agenus Inc. is an immunotherapy company with innovative research, facing significant hurdles. Positive clinical trial data and strategic collaborations are driving forces. Limited financial resources and intense competition are key challenges. Its success depends on successfully navigating the regulatory landscape and commercializing its pipeline. The company is in an early stage of growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings (10-K, 10-Q)
  • Company press releases
  • Analyst reports
  • Industry reports
  • Company Website

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Financial data and market information are subject to change. The AI-based rating is a general assessment and should not be the sole basis for investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Agenus Inc

Exchange NASDAQ
Headquaters Lexington, MA, United States
IPO Launch date 2000-02-04
Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 316
Full time employees 316

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.